Meredith  Ervine

Meredith Ervine is a corporate attorney focusing her practice on securities and corporate governance matters. Over the course of her career, she has worked on more than 65 securities offerings involving more than $11.3 billion. She has experience representing clients across many industries on securities issues, mergers and acquisitions, and general corporate matters, focusing primarily on public and pre-IPO companies.

• Advises clients regarding compliance with the securities laws, including the reporting requirements of the SEC and the national securities exchanges
• Assists clients in connection with annual and special stockholder meetings, including preparation of proxy statements
• Counsels clients in public and private offerings of both debt and equity securities
• Advises clients on corporate governance best practices
• Counsels clients on transactional matters, including corporate finance and mergers and acquisitions
• Assists clients with general contract and planning matters

Representative Clients

• Represents a Midwest-based medical device company listed on Nasdaq
• Represents a Midwest-based clinical-stage biopharmaceutical company listed on Nasdaq
• Represents a Midwest-based, development stage medical device company on the OTC Pink Sheets
• Represents a retail chain specializing in home décor products headquartered in Texas and listed on the NYSE
• Serves as secondary counsel to a media and entertainment company that is headquartered in Connecticut and listed on the NYSE
• Serves as special or secondary counsel to three Northeast-based unaffiliated controlled companies (wholesale/retail fashion, wholesale/retail consumer goods, and manufacturer of advanced materials) listed on the NYSE
• Advised a Northeast-based plastic packaging films manufacturer listed on Nasdaq

Recent Transactions

• $145 million sale of electronics division of NYSE-listed company to a buyer headquartered in Japan
• Reverse merger of a development-stage medical device company into the wholly-owned subsidiary of an OTC Pink Sheets reporting company
• Public offering of Class A and Class B Units for a Nasdaq-listed medical device company
• PIPE transaction of common stock and warrants for a Nasdaq-listed clinical stage biopharmaceutical company
• Establishment of a $50 million at-the-market equity program for a Nasdaq-listed biopharmaceutical company
• Co-lead counsel on $785 million sale of plastic packaging films manufacturer (Nasdaq) through merger to an NYSE-listed company
• $65 million common stock rights offering and backstop commitment (NYSE) for leading contemporary fashion brand (represented the independent directors)
• $30 million initial public offering of common stock (Nasdaq) for a clinical-stage biopharmaceutical company
• Registered direct offerings of preferred stock and warrants for a Nasdaq-listed medical device company

Grand Rapids Ballet

• Board Member, 2017
• Development Committee Member, 2017